|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003315,
umls-concept:C0021083,
umls-concept:C0030705,
umls-concept:C0205195,
umls-concept:C0205473,
umls-concept:C0312402,
umls-concept:C0376358,
umls-concept:C0443196,
umls-concept:C0449258,
umls-concept:C0796392,
umls-concept:C1135133,
umls-concept:C1517925,
umls-concept:C1947910
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-6-22
|
|
pubmed:abstractText |
APC8015 (sipuleucel-T) is a cellular prostate cancer vaccine containing autologous antigen-presenting cells (APC) loaded with PA2024, a recombinant prostatic acid phosphatase/granulocyte-macrophage-colony-stimulating factor fusion protein, as the immunogen. Bevacizumab is a recombinant antibody against vascular endothelial growth factor, a proangiogenic protein with inhibitory effects on APC. A clinical trial was conducted to determine the prostate-specific antigen (PSA) and immunomodulatory effects of this combination immunotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Tyrosine Phosphatases,
http://linkedlifedata.com/resource/pubmed/chemical/Tissue Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/prostatic acid phosphatase,
http://linkedlifedata.com/resource/pubmed/chemical/sipuleucel-T
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
67-74
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16736512-Aged,
pubmed-meshheading:16736512-Angiogenesis Inhibitors,
pubmed-meshheading:16736512-Antibodies, Monoclonal,
pubmed-meshheading:16736512-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16736512-Antigen-Presenting Cells,
pubmed-meshheading:16736512-Cancer Vaccines,
pubmed-meshheading:16736512-Combined Modality Therapy,
pubmed-meshheading:16736512-Disease Progression,
pubmed-meshheading:16736512-Humans,
pubmed-meshheading:16736512-Immunotherapy,
pubmed-meshheading:16736512-Lymphocyte Activation,
pubmed-meshheading:16736512-Male,
pubmed-meshheading:16736512-Middle Aged,
pubmed-meshheading:16736512-Prostate-Specific Antigen,
pubmed-meshheading:16736512-Prostatic Neoplasms,
pubmed-meshheading:16736512-Protein Tyrosine Phosphatases,
pubmed-meshheading:16736512-T-Lymphocytes,
pubmed-meshheading:16736512-Tissue Extracts
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
|
|
pubmed:affiliation |
Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA. rinib2@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
